The Effect of Recombinant Baculovirus (BacG-CMV-P53) Mediated Gene Therapy in the HT-1376 Bladder Cancer Cell Line / 대한비뇨기과학회지
Korean Journal of Urology
;
: 1156-1161, 2004.
Article
in Korean
| WPRIM
| ID: wpr-137452
ABSTRACT
PURPOSE:
In preliminary studies, it was found that mammalian cells can be infected by recombinant baculovirus in vitro. Therefore, the potential use of recombinant baculovirus(BacG-cytonegalovirus(CMV)-P53) for the bladder gene therapy was investigated. MATERIALS ANDMETHODS:
The recombinant Baculovirus(BV) pseudotyped was developed with the vesicular stomatitis virus(VSV) G protein. The presence of the VSV-G protein in purified BV preparations was confirmed by Western blotting analysis. The bladder cancer cells of human(HT-1376) were infected with various multiplicity of infection(MOI) of the BV, and the percentage of apoptotic cells determined by methyl thiazolyl tetrazolium(MTT) assay.RESULTS:
The suppression effect of the recombinant BV with a P53 insertion in human bladder cancer cells(HT-1376) increased as the MOI of the recombinant BV increased; 100% cell survival in the group with PBS, and 81.6+/-4.3, 52.0+/-5.6 and 39.8+/-3.7% at 1, 10 and 100 MOI, respectively (p<0.05).CONCLUSIONS:
Significant growth suppression was observed following infection with BacG-CMV-P53 in a human bladder cancer cell line. This observation suggests that BacG-CMV-P53 may be a potentially effective agent to prevent recurrence for P53 mutated bladder cancer. Bladder gene therapy using recombinant baculovirus could be a safe and effective treatment of bladder cancer.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Recurrence
/
Urinary Bladder
/
Urinary Bladder Neoplasms
/
Genetic Therapy
/
Cell Line
/
Cell Survival
/
Blotting, Western
/
Baculoviridae
/
GTP-Binding Proteins
/
Vesicular Stomatitis
Limits:
Humans
Language:
Korean
Journal:
Korean Journal of Urology
Year:
2004
Type:
Article
Similar
MEDLINE
...
LILACS
LIS